Fintel reports that on August 12, 2024, Deutsche Bank upgraded their outlook for Eli Lilly and (NYSE:LLY) from Hold to Buy.
Analyst Price Forecast Suggests 6.27% Upside
As of August 5, 2024, the average one-year price target for Eli Lilly and is $947.61/share. The forecasts range from a low of $606.00 to a high of $1,172.85. The average price target represents an increase of 6.27% from its latest reported closing price of $891.68 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Eli Lilly and is 35,769MM, a decrease of 8.10%. The projected annual non-GAAP EPS is 12.40.
What is the Fund Sentiment?
There are 5,091 funds or institutions reporting positions in Eli Lilly and. This is an increase of 175 owner(s) or 3.56% in the last quarter. Average portfolio weight of all funds dedicated to LLY is 1.25%, an increase of 12.02%. Total shares owned by institutions decreased in the last three months by 1.85% to 861,955K shares. 
The put/call ratio of LLY is 0.94, indicating a bullish outlook.
What are Other Shareholders Doing?
Lilly Endowment holds 97,367K shares representing 10.81% ownership of the company. In its prior filing, the firm reported owning 98,899K shares , representing a decrease of 1.57%.
Pnc Financial Services Group holds 51,405K shares representing 5.71% ownership of the company. In its prior filing, the firm reported owning 51,438K shares , representing a decrease of 0.06%. The firm decreased its portfolio allocation in LLY by 80.98% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 26,883K shares representing 2.99% ownership of the company. In its prior filing, the firm reported owning 26,821K shares , representing an increase of 0.23%. The firm increased its portfolio allocation in LLY by 21.95% over the last quarter.
Capital World Investors holds 24,536K shares representing 2.72% ownership of the company. In its prior filing, the firm reported owning 26,950K shares , representing a decrease of 9.84%. The firm increased its portfolio allocation in LLY by 13.07% over the last quarter.
Price T Rowe Associates holds 20,613K shares representing 2.29% ownership of the company. In its prior filing, the firm reported owning 21,827K shares , representing a decrease of 5.89%. The firm increased its portfolio allocation in LLY by 14.97% over the last quarter.
Lilly Background Information
(This description is provided by the company.)
Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. It was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today it remains true to that mission in all its work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
